Applies to Employer and ACA Marketplace plans.
Covered (preferred drug)Qualification pathways
You can qualify through any one of these.
CKD with T2DM
All of:
- Diagnosis of type 2 diabetes
- A1C ≥ 6.5% confirmed by lab test or medical records
- Patient has chronic kidney disease (CKD)
- Requested agent will be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
- Patient will NOT use requested agent in combination with a DPP-4 containing agent
- Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications to the requested agent
- Patient age is within FDA labeling OR there is support for use outside labeled age range
Documentation to bring
- Documentation of type 2 diabetes diagnosis
- Lab test results or medical records confirming A1C ≥ 6.5%
- Documentation of chronic kidney disease (CKD) diagnosis
- Confirmation that requested agent will be used to reduce sustained eGFR decline, ESKD, or cardiovascular death
- Confirmation that patient will not use with DPP-4 containing agent
- Confirmation that patient will not use with another GLP-1 receptor agonist
Quantity limits
- 2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen per 28 days
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: Continuation requires prior preferred agent use within 90 days or prescriber attestation of risk if discontinued.
Not covered when
- Combination with DPP-4 containing agents not permitted
- Combination with another GLP-1 receptor agonist not permitted
- FDA labeled contraindications to the requested agent
- Personal or family history of MTC or MEN 2
- Prior serious hypersensitivity reaction to semaglutide or product components
Policy note: CKD is a qualifying pathway under the diabetes PA criteria. The policy requires T2DM diagnosis AND A1C ≥ 6.5% in addition to CKD. Specific eGFR or UACR thresholds are not defined in this policy. No specific CKD staging requirements are listed.
Policy effective May 11, 2026 · verified June 2, 2026 · source: Ks GLP-1 Prog Sum · View policy document (PDF)